Year All2026202520242023202220212020 July 6, 2026 Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA July 2, 2026 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 16, 2026 Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine June 9, 2026 Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration June 3, 2026 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 1, 2026 Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID May 27, 2026 Invivyd to Participate in Upcoming Investor Events May 14, 2026 Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights May 11, 2026 Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination May 7, 2026 Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
